SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs with significant premiums reported in Shanghai. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers, leading many to anticipate a massive "silver squeeze" and a re-rating of its value. While bulls foresee further exponential gains, some community members anticipate a near-term pullback after its rapid ascent.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending amidst significant network upgrades, including the rollout of Polkadot 2.0 featuring elastic scaling, a new supply cap for DOT with halving emissions, and a migration of governance and staking to its Asset Hub chain. Community sentiment is notably divided, with proponents viewing these tokenomic shifts as strong bullish catalysts for long-term growth and others expressing deep skepticism regarding past performance and future prospects. These developments also unfold alongside discussions of its interoperability within the broader crypto ecosystem and ongoing dialogues around potential crypto ETF approvals.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors celebrate the recent FDA approval of YARTEMLEA, the first and only treatment for a life-threatening post-transplant complication, sparking a fervent discussion on its potential. The community believes the stock is significantly undervalued, pointing to a strategic partnership with Novo Nordisk and a strong pipeline, fueling speculation of a massive short squeeze and potential buyout. Anticipation is high for further details on commercialization plans and pricing, with many urging long-term holds.

Direxion Shares ETF Trust - Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares is trending as the broader S&P 500 index recently achieved new record highs, fueling fervent bullish sentiment. The community is actively debating whether this marks the continuation of an upward rally, prompting many to buy dips and leverage for amplified gains. While economic indicators and discussions around central bank policies add context, traders are keenly focused on riding the market's momentum.

abrdn ETF - abrdn Physical Silver Shares ETF

SIVR is trending as silver prices achieve significant highs, driven by strong investor demand for safe-haven assets and expectations of loosening monetary policy. The community is actively discussing silver's breakout, citing perceived undervaluation, tightening supply, and increasing industrial demand amid global economic uncertainties. Many anticipate continued upward movement, seeing silver as a critical hedge against inflation and a weaker dollar.

A community-driven memecoin created to protect and empower crypto users, CTOs, and low-marketcap gems. Our ecosystem features weekly crypto talks/hosting services, a “Most Wanted" scam tracker, and a "Portfolio" with partnered projects. We help others succeed through long-term partnerships and services.   Weekly Hosting: a weekly hosting service where the team and community come together to talk about crypto and project updates. We will invite guests from rugged projects who want to talk/share insight, invite CTO/low market cap projects to come speak about what they are doing, and give dedicated time for partnered projects to speak on updates for our listeners.   Portfolio: a webpage designated to embrace CTOs or smaller cap projects with an established following.  Partnered projects commit to a discussed rate to help fuel growth of the RCON token and their own, through a structured revenue distribution model (detailed below).  Tokens will be held as long as the partnered project remains active.  12.5% buys RCON coin and burns 12.5% sent to RCON marketing wallet 12.5% used for LP/Pairing [RCON and partnered token] on ORCA 12.5% dedicated to community outreach 50% buys and holds initial value of partnered token  Most Wanted: a webpage designated to expose chronic offenders / scammers / ruggers.  Our project can help those navigate the cryptocurrency space safely.

Recon Raccoon

RCON CRYPTO is gaining attention as the community actively discusses significant portions of its token supply being locked, earmarked for future Centralized Exchange listings and long-term team vesting. Investors are highlighting the project's committed team and its detailed vision as pivotal factors driving interest and future potential.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is a prominent talking point as the market reacts to escalating global tensions and China's increased control over critical mineral exports. Investors are keenly focused on UAMY's established role as a key domestic supplier, particularly for military-grade antimony, and its ongoing capacity expansion to meet growing strategic demand amidst skepticism surrounding emerging competitors.

xCellar is a DeFi protocol powered by the Fawkes Formula, providing untraceable and secure transactions on the blockchain. It's designed to give users complete financial privacy and control over their assets. The Fawkes Formula is our proprietary security protocol that forms the core of xCellar's untraceable transaction system. It utilizes advanced zero-knowledge proofs and cryptographic techniques to ensure complete anonymity.

Xcellar

Xcellar ($XCL) is trending amid discussions of its new protocol updates nearing completion and the approaching conclusion of the Sentinel token presale, which is expected to drive supply burns and reward distribution. The community is actively highlighting XCL's resilient performance, significant past gains, and its core focus on providing anonymous transactions and passive income opportunities for holders. Many investors are viewing recent price pullbacks as opportune entry points, anticipating substantial long-term growth within the privacy-focused crypto sector.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending with highly polarized sentiment, as its dedicated community anticipates a significant upward move and a 'Christmas rally', while a vocal group expresses skepticism, labeling it a 'scam' and noting its extended period of underperformance. The conversation actively centers on token burning initiatives and comparisons to other meme coins, reflecting broader market speculation on altcoin viability.

abrdn ETF - abrdn Physical Platinum Shares ETF

abrdn Physical Platinum Shares ETF (PPLT) is experiencing a notable surge in trading volume and price, fueled by strong community sentiment anticipating a significant breakout. Discussions highlight platinum's projected supply deficits, rising industrial demand for automotive catalysts and green energy, and its perceived undervaluation relative to gold. This bullish outlook is further intensified by geopolitical risks affecting key mining regions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuron (IMRN) CEO Steven Lydeamore stated in a letter to shareholders on Thursday that the company does not anticipate any material impact from the recently announced U.S. tariffs on pharmaceutical products.Nasdaq-listed shares of Immuron rallied 8% on Thursday morning following the news. The CEO <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160195/37134/en/Immuron-Letter-to-Shareholders-Projects-Update.html">stated</a> that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs.The Australia-based company also said that it is on track to exceed FY24 first-quarter (Q1) sales. The company is slated to report its Q1 FY25 sales in mid-October.Immuron has three therapeutic products under development, including IMM-124E, also known as Travelan, for traveler’s diarrhea. The company stated that it continues to expect trial results for this candidate in October 2025.“It is hoped that this trial will enable Travelan to be recommended in traveler’s diarrhea guidelines, thereby increasing its market potential,” the company said.As for IMM-529, which is under development for Clostridioides difficile infection, Immuron stated that it is progressing with an application to the U.S. Food and Drug Administration to initiate clinical development by mid-October. According to Immuron, the IMM-529 market in the U.S. is expected to reach peak revenues of approximately $400 million.The company has also advanced the launch of ProIBS, a medical product for treating symptoms related to Irritable Bowel Syndrome, to the fourth quarter from its previous estimate of Q1 2026. Immuron now anticipates a limited launch in Q4, with a full launch in Q1 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMRN">IMRN stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:574/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_12_28_03_PM_png_c36282e1fb.webp" alt="IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="574" height="58"><figcaption>IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the company’s updates.<stembedurl>https://stocktwits.com/Timtheshark/message/630768842</stembedurl>IMRN stock is up 22% this year but down approximately 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reports-7-percent-rise-in-q3-deliveries/chCrXlDR3Ow">Tesla’s Q3 Deliveries Hit Quarterly Record, Rise 7% To Exceed Analyst Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 

Equity

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 


Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

IMRN
IMMURON Ltd/S ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IMRN News

IMRNIMMURON Ltd/S ADR